New attack on liver cancer: testing a powerful drug duo with targeted artery treatments
NCT ID NCT07380633
Summary
This trial is testing a combination of two approved drugs (toripalimab and bevacizumab) with three different procedures that deliver treatment directly into the liver's arteries. The goal is to see which combined approach works best to shrink tumors and control advanced liver cancer that cannot be removed by surgery. It will involve 90 patients to measure how long the cancer stays under control and the safety of the treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Conditions
Explore the condition pages connected to this study.